Incidence of mutations in mCRC patients

ESMO guidelines recommend that 'Tumour BRAF mutation status should be assessed alongside the assessment of tumour RAS mutational status'6

approximately

50%

RAS

mutations7

up to

12%

BRAF

mutations7

Visit www.testmCRCmutations.com to learn more

Why test?6

  • Adhere to ESMO guideline recommendations, which base the use of cytotoxics and biologicals on molecular profile
  • Gain a deeper knowledge of the impact and clinical relevance of mutations
  • Promote enrolment of patients into clinical trials with new targeted approaches
  • Improve outcomes for patients with mCRC

Molecular heterogeneity of colorectal cancer is substantial

The MAPK pathway is the most frequently dysregulated signalling pathway linked to various cancers, such as colorectal cancer. Key drivers for the aberrant MAPK signalling are mutations in the downstream pathway components RAS or BRAF.1,2

Created from Refs. 1, 2
EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase.

Patients with mCRC with RAS- or BRAF-mutated tumours may have poorer outcomes than those with wild-type tumours

RAS- and, to a greater extent, BRAF-mutated tumours may be associated with a poorer prognosis than RAS and BRAF wild-type tumours, based on retrospective analyses of clinical trial data3-5

Overall survival according to molecular subgroups in 357 patients with mCRC receiving first-line treatment3

Adapted from the TRIBE study: Ref. 3
According to the study protocol, the mutation status of KRAS codons 12, 13, and 61 and of BRAF codon 600 was assessed

ND/ONC/10/21/0001

Referenser
1 Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy. Santarpia L, et al. Expert Opin Ther Targets 2012;16:103-19.
2 Targeting ERK, an Achilles 'Heel of the MAPK pathway, in cancer therapy. Liu F, et al. Acta Pharm Sin B 2018;8:552-62.
3 FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Cremolini C, et al. Lancet Oncol. 2015;16(13):1306-1315.
4 Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Stintzing S, et al. Eur J Cancer 2017;79:50-60.
5 Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for secondline treatment (tx) of metastatic colorectal cancer (mCRC). Peeters M, et al. J Clin Oncol 2014;32: A3568.
6 ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Van Cutsem E, et al. Ann Oncol 2016;27:1386-422.
7 Unmet Medical Need in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutations: A Review. Tabernero J, et al. EMJ Oncol 2020; 8[Suppl 3]:2-14.
Pierre Fabre använder cookies och andra spårningsfunktioner för att optimera webbplatsens prestanda och funktionalitet, mäta målgruppen och anpassa innehållet (annonseringen) efter dina intresseområden. Mer information om hanteringen av dina personuppgifter och dina rättigheter finns i vår sekretesspolicy. Om du vill ställa in eller inaktivera cookies klickar du på Cookie-inställningar.
Är du hälso- och sjukvårdspersonal?
Denna site är avsedd för hälso- och sjukvårdspersonal i Sverige, klicka ja nedan så kommer du in på webbplatsen. Klickar du nej kommer du till
pierre-fabre.com/se-se.
NEJ

Du öppnar nu en extern webbplats


Pierre-Fabre ansvarar inte för innehållet på andras hemsidor. Klicka på "Öppna länk" om du vill fortsätta.
Öppna länk